Clinical Care

Revised Glioblastoma Classification Should Improve Patient Care
Radiation oncology researchers have revised the prognostic model used by doctors since the 1990s for glioblastoma, the most devastating of malignant brain tumors. The previous system was devised for malignant glioma patients who were treated by radiation therapy only, relying on histopathology and clinical variables. The new system accommodates advances in treatment – particularly the use of radiation therapy plus the chemotherapy drug temozolomide – and it incorporates molecular biomarkers as well as clinical variables. Arnab Chakravarti, MD, the study’s national chair for translational research and co-leader of the brain tumor program at the OSUCCC – James, says the new model is more relevant and should better identify patients requiring the most aggressive therapy.
Surgeons Pioneer Removal of Skull Base Tumors Through Nose and Mouth
Surgeons at the OSUCCC – James Cranial Base Center developed a minimally invasive technique to reach and remove skull base tumors through the nose or mouth, sparing patients considerable pain from traditional open surgery and allowing for quicker recovery. The procedure combines endoscopic endonasal surgery with minimally invasive robotic surgery to treat many tumors that are difficult to reach, including some previously considered inoperable. The endoscopic endonasal approach gives surgeons access to the base of the skull, intracranial cavity and top of the spine by operating through the nose and paranasal sinuses. The surgical team includes Ricardo Carrau, MD, Daniel Prevedello, MD, and Enver Ozer, MD.,-Sparing-Patients-From-Open-Brain-Surg.aspx

OSU Leads International Pancreatic Cancer Treatment Development Effort
The OSUCCC – James is leading an international pancreatic cancer research effort in collaboration with scientific investigators based in Taiwan and Germany to develop new targeted therapies and biomarkers for pancreatic cancer. Tanios Bekaii-Saab, MD, section chief for gastrointestinal oncology at the OSUCCC – James, and Cheng-Shih Chen, PhD, of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, are partnering with doctors at National Cheng-Kung University in Tainan City, Taiwan, and with researchers at the German Cancer Research Center in Heidelberg, to conduct the initiative. The researchers will work to identify new targets in pancreatic tumors and develop novel agents to strike those targets and halt the progression of this disease, for which the overall five-year survival rate is only 5.8 percent.


The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: